한국바이케미칼

비상장계속사업자

HANKOOK BAYCHEMICAL CO., LTD.

이의배

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

한국바이케미칼

Business Reg. No. 2138192105 · CEO 이의배

I.Investment Overview

Target한국바이케미칼 (2138192105)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명한국바이케미칼
영문명HANKOOK BAYCHEMICAL CO., LTD.
대표자이의배
사업자등록번호2138192105
법인등록번호1101111058935
설립일1994.07.25
종업원수13명

V.Workforce

13

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW93.220202332022237.72023291.22024157.62025
영업이익100M KRW-6.920202620229.620231520244.32025
순이익100M KRW-1.2202022.520226.8202310.620241.62025
Item20252024202320222020
자산총계160.1억원181.9억원190.3억원201.6억원116.8억원
부채총계54.9억원73.3억원88.2억원100.2억원39.6억원
자본총계105.2억원108.6억원102.1억원101.3억원77.2억원
매출액157.6억원291.2억원237.7억원233억원93.2억원
영업이익4.3억원15억원9.6억원26억원-6.9억원
순이익1.6억원10.6억원6.8억원22.5억원-1.2억원

VII.Financial Ratios

FY2025 basis

2.7%

영업이익률

1.02%

순이익률

1.01%

ROA

1.53%

ROE

52.16%

부채비율

65.72%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

한국바이케미칼 투심보고서 | Alpha Lenz